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Aim 
A recent systematic review highlighted the lack of robust studies on prescribers’ 
perspectives of direct-acting oral anticoagulants (DOACs) for non-valvular atrial 
fibrillation (AF). The aim was to determine prescribers’ views and experiences of 
prescribing DOACs.  
Methods 
A cross-sectional survey of prescribers in a remote and rural area of Scotland. Survey 
items were: demographics; prescribing of DOACs; views of potential influences on DOAC 
prescribing; knowledge of prescribing guidelines; and experiences. Items on potential 
influences were based on the Theoretical Domains Framework (TDF). Data were 
analysed using descriptive and inferential statistics, and content analysis of responses to 
open questions. Principal component analysis (PCA) was performed on the items of 
potential influences. 
Results  
One hundred and fifty-four responses were received, 120 (77.9%) from doctors, 18 
(11.7%) from nurse prescribers and 10 (6.4%) from pharmacist prescribers (6 missing). 
PCA of the TDF items of potential influences gave four components. Component scores 
for (i) role of professionals, their knowledge and skills and (ii) influences on prescribing 
were positive. Those for (iii) consequences of prescribing and (iv) monitoring for safety 
and effectiveness were more neutral. There were low levels of agreement for statements 
relating to DOACs being more effective, safer and cost-effective than warfarin. There 
were similar responses around the complexity of bleeding management and detection of 
over and under-anticoagulation.  
Conclusion 
This study has identified several key issues of DOAC prescribing (e.g. bleeding 
management) hence further emphasis is required in continuing professional development 
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What is already known about this subject  
 Little attention has been paid to prescribers’ views and experiences DOACs in the 
management of non-valvular AF 
 A recent systematic review identified only nine surveys and one qualitative study, 
with key limitations in study design and reporting hence views and experiences 
are relatively unknown 
 
 
What this study adds  
 This study is a theory based cross-sectional survey of prescribers in a remote and 
rural area of Scotland  
 Findings identified a lack of awareness of the evidence base of the effectiveness, 
safety and cost-effectiveness of DOACs. There were issues around the 
management of DOAC related bleeding and the identification of over and under-
anticoagulation. 
 Further emphasis of these aspects are required during continuing professional 
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Introduction 
The management of non-valvular atrial fibrillation (AF) significantly altered with the 
advent of the direct-acting oral anticoagulants (DOACs) dabigatran, rivaroxaban, 
apixaban and edoxaban. DOACs have replaced warfarin as first line in many national and 
international guidelines and policy statements, including those of the National Institute 
for Health and Care Excellence in England and Wales [1], the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines/Heart Rhythm 
Society [2], the European Society of Cardiology [3], and the European Heart Rhythm 
Association [4].  
Guideline recommendations are based on the evidence collated in systematic reviews 
and meta-analyses of efficacy, effectiveness and safety. The perspectives of prescribers 
on this new class of pharmacological agents has, however, received much less attention. 
The only systematic review of prescribers’ views and experiences of DOACs, published in 
2018, yielded only ten peer-reviewed studies from January 2006 to July 2017 [5]. Cross-
sectional surveys, conducted in Europe and North America, reported views and 
experiences of general practitioners (GPs), cardiologists, general internists, hospital 
doctors, non-medical prescribers, members of associations and research networks. Study 
aims were heterogeneous, as were the specific questionnaire domains and items. Two 
studies reported factors influencing DOAC use [6,7]; six preference for DOACs over 
warfarin [6-11]; two issues with clinical guidelines [8,12]; and three issues in DOAC use 
[7,9,13]. In the six studies of prescriber preference, DOACs were first choice for warfarin 
naïve patients, largely based on perceptions of effectiveness, and were considered 
advantageous in patients with unstable International Normalized Ratios or likely to miss 
appointments. Concerns mainly related to the management of over anticoagulation and 
bleeding.  
The findings of these surveys, and hence the systematic review, are limited by the 
response rates of 9-35.9%, with participant numbers ranging from 38-450 [5]. One 
further limitation is the omission of theory (e.g. cognitive, behavioural, organisational) 
as part of questionnaire development. Considering the theoretical basis will yield a data 
collection tool with comprehensive coverage of all key factors leading to more valid 
findings [14,15]. There is therefore a need to systematically research the views and 
experiences of prescribers, using a robust approach which will take account of these 
limitations. This will allow elucidation of positive and negative views and factors 
influencing prescribing which could be used to further optimise DOAC use.   
The aim of this study was to apply theory to determine prescribers’ views and 
experiences of prescribing DOACs for the management of non-valvular AF. 
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Method  
Research design 
The design was a cross-sectional survey using an online questionnaire.  
 
Setting 
The research was conducted across primary and secondary care within NHS Highland in 
Scotland. This is an area of low population density covering approximately 40% of the 
land mass of Scotland yet representing only 6% of the Scottish population. Forty percent 
of residents are within ‘remote rural’ locations [16]. Responsibility for the management 
of stroke prevention in patients with AF is usually undertaken in primary care although 
patients can also be initiated on therapy in secondary care if they attend outpatient 
clinics or during admission. 
 
Inclusion and exclusion criteria 
All medical prescribers of all grades and non-medical prescribers (e.g. nurse and 
pharmacist independent prescribers) were invited to participate, with no exclusions. 
 
Questionnaire development 
A draft questionnaire was developed based on the recent systematic review conducted 
by the research team [5]. The draft was reviewed for face and content validity by six 
experienced researchers and practitioners identified from professional networks followed 
by ‘think aloud testing’ with one medical and one non-medical prescriber. Piloting was 
undertaken in a sample of 30 prescribers based outside NHS Highland. The final version 
of the questionnaire was formatted in Snap 10 Professional® (software for web and 
email questionnaire design, publication, data entry and analysis) and tested for 
compatibility with platforms (e.g. tablet, smartphone), browsers, and NHS email and 
internet filters. 
Questionnaire items were grouped into sections of: demographics; DOAC prescribing 
(approximate frequency of initiation, switching and discontinuation); potential influences 
on DOAC prescribing; knowledge of local prescribing guidelines; and experiences. 
Question types were closed, 5-point Likert scales and open to allow comment. Items on 
potential influences on prescribing were based on the Theoretical Domains Framework 
(TDF, derived from the constructs of 33 behaviour change theories) [17]. TDF domains of 
determinants (influences) of behaviour are clustered into: knowledge; skills; 
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social/professional role and identity; beliefs about capabilities; optimism; beliefs about 
consequences; reinforcement; intentions; goals; memory, attention and decision 
processes; environmental context and resources; social influences; emotions; and 
behavioral regulation. The TDF Determinants of Implementation Behavior Questionnaire 
(DIQB) was used in the development of the individual items. DIQB is a valid and reliable 
tool with items aligned to each of the TDF domains which researchers can select and 
adapt those relevant to the behaviour under study (i.e. prescribing DOACs) [18]. In the 
personal demographics section, respondents classified themselves as ‘innovators’, ‘early 




An email with a link to the participant information leaflet and questionnaire was sent to 
all prescribers within the NHS Highland database. The email indicated that the 
questionnaire be completed only by those either currently prescribing DOACs or likely to 
do so in the near future. The following evidence based measures were adopted to 
maximise survey response rate: two email reminders sent at 4-weekly intervals; an 
information leaflet outlining the study aim, potential benefits and assuring anonymity; 
and a visually attractive questionnaire [20]. Data collection took place from April to July 
2017.  
 
Data analysis  
Data were analysed using descriptive and inferential statistics, and content analysis of 
responses to open items. The 5-point Likert scale TDF items were subjected to principal 
components analysis (PCA) to reduce the large number of items to a smaller, more 
manageable number of components [21]. Data suitability for PCA was tested via 
determination of the: correlation matrix for co-efficients (≥0.3); Kaiser-Meyer-Olkin 
measure of sampling adequacy (≥0.6); and Bartlett’s test of sphericity (≤0.05). The 
number of components was determined via Eigenvalues >1 and visual inspection of the 
scree plot. Varimax rotation was used to aid the interpretation of the components as, 
from a theoretical perspective, there was reason to assume that selected attitudinal 
items were correlated; missing data were excluded pairwise [22]. Where items cross 
loaded onto more than one component, the item was captured within the component of 
highest loading. Internal consistencies of the resulting component(s) were tested using 
Cronbach’s alpha, aiming for >0.60 as desirable for psychometric scales [21]. Total 
component scores were obtained by assigning scores of 1 (strongly disagree) to 5 
(strongly agree) to each of the Likert statement responses, with negatively worded items 
being reverse scored, and generating a summed score for each component. Differences 
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in total component scores between demographic groupings (medical/non-medical 
prescriber, setting, experience as health professional and prescriber) were tested using 
Mann-Whitney U test (2 groups) or Kruskal-Wallis (>2 groups). Free text comments 
were handled using a content analysis approach [23]. 
 
Ethics 
This study was approved by the Ethical Review Panel of the School of Pharmacy and Life 
Sciences at Robert Gordon University, UK; the North of Scotland Research Ethics 
Committee advised that the study was exempt from NHS ethical review. Management 
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Results 
Demographics 
One hundred and fifty-four responses were received, 120 (77.9%) from doctors 
(including 76 general practitioners), 18 (11.7%) from nurse prescribers and 10 (6.4%) 
from pharmacist prescribers (6 missing). Respondents had a mean age of 43.3 years 
(standard deviation 11.9 years). Just over half (n=84, 54.5%) had twenty of more 
years’ experience as health professionals and slightly less (n=61, 39.6%) as prescribers. 
Around one quarter (n=34, 22.1%) rated themselves as ‘innovators’, 25 (16.2%) as 
‘early adopters’ and none as ‘laggards’ (Table 1). A response rate could not be calculated 
as the total number of prescribers either currently prescribing DOACs or likely to do so in 
the near future was unknown.  
DOAC prescribing 
Current practice relating to DOAC prescribing is given in Table 2. The most common 
behaviour was continuing DOACs if initiated by others (n=112, 72.8% weekly or 
monthly). Sixty-six respondents (42.9%) initiated DOACs either weekly or monthly.  
Sixteen respondents (10.4%) never prescribed DOACs and had no plans to prescribe in 
the future, hence were removed from any further analysis. These sixteen were seven 
nurses, five doctors, two physiotherapists, one pharmacist and one podiatrist.  
 
Knowledge of NHS Highland Guidelines  
While respondents were largely aware of the guidelines in terms of when to consider 
DOACs (correct response n=99, 71.9%) and that dabigatran was the DOAC of choice [at 
the time of the study] (correct response n=99, 71.9%), fewer knew that apixaban was 
not the second choice (correct response n=76, 57.2%) and that patients must be able to 
swallow capsules whole before prescribing dabigatran (correct response n=67, 48.6%) 
 
Principal component analysis 
When items on potential influences on prescribing were subjected to PCA, the correlation 
matrix contained multiple coefficients above 0.3. The Kaiser–Meyer–Olkin measure of 
sampling adequacy (0.721) and Bartlett’s test of sphericity (significance <0.001) 
confirmed the factorability of the items. Consideration of the number of components with 
Eigenvalues exceeding 1.0 and the Scree plot gave a four-factor solution explaining of 
48.9% of the variance. The four components were labelled: ‘the role of professionals, 
their knowledge and skills’ (Cronbach’s alpha 0.904); ‘influences on prescribing’ 
(Cronbach’s alpha 0.802); ‘consequences of prescribing’ (Cronbach’s alpha 0.714); and 
‘monitoring for safety and effectiveness’ (Cronbach’s alpha 0.612).  
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Component 1 ‘the role of professionals, their knowledge and skills’ (Table 3) 
Respondents generally held positive views, with a median overall score of 61 (IQR 54-
64), range possible 16-80 (midpoint 48), with 80 representing the highest possible 
positive score. The statements with the lowest levels of agreement were ‘I find the 
guidelines on DOACs easy to interpret’ (agree/strongly agree n=58, 42.1%) and ‘I have 
sufficient knowledge of how to manage adverse reactions of DOACs’ (agree/strongly 
agree n=64, 46.4%). Two thirds (n=92, 66.7%) agreed/strongly agreed that they were 
competent to initiate DOACs and slightly less (n=85, 61.6%) confident. Just over one 
quarter (n=36, 26.0%) found it difficult to decide between DOACs or warfarin. 
Component 1 scores were statistically significantly higher for those based in primary care 
(Mann-Whitney U, p<0.05), more experienced as health professionals (Kruskal-Wallis, 
p<0.05) and more experienced as prescribers (Kruskal-Wallis, p<0.001).  
Component 2 ‘influences on prescribing’ (Table 4)  
With a median value of 19 and IQR of 17-20 (5-25, midpoint 15), respondents generally 
gave positive responses. The statements with the lowest levels of positive responses 
were ‘cost is a deterrent to my prescribing of DOACs’ (agree/strongly agree n=40, 
29.0%) and ‘potentially increased scrutiny of my prescribing by the health board is a 
deterrent to my prescribing of DOACs’ (agree/strongly agree n=27, 19.6%). Component 
2 scores were statistically significantly higher for those based in secondary care (Mann-
Whitney U, p<0.05). 
Component 3 ‘consequences of prescribing’ (Table 5) 
Responses to this component were generally more neutral with a median value of 19 and 
IQR of 17-21.25 (range possible 6-30, midpoint 18) respondents generally gave more 
neutral responses. Fifty-three respondents (38.4%) scored the midscale point of 18 or 
less. The statements with the lowest levels of agreement were around patients being 
treated more effectively with DOACs compared to warfarin (agree/strongly agree n=39, 
28.2%), having less adverse effects (agree/strongly agree n=28, 20.3%) and being 
treated more cost-effectively (agree/strongly agree n=23, 16.7%). Component 3 scores 
were statistically significantly higher for those based with less experience as prescribers 
(Kruskal-Wallis, p<0.05). 
Component 4 ‘monitoring for safety and effectiveness’ (Table 6)  
With a median value of 17 and IQR of 14-19 (minimum 9, maximum 25), respondents 
gave more neutral responses. Thirty-eight respondents (27.5%) of respondents scored 
the midscale point of 15 or less. Respondents were largely in agreement that 
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management of bleeding on DOACs was more complex than warfarin (agree/strongly 
agree n=89, 42.8%). Just under half agreed/strongly agreed that over-anticoagulation 
(n=59, 42.8%) and under-anticoagulation (n=60, 43.4%) with DOACs would not be 
easily detected. 
Component 4 scores were statistically significantly higher for those with more experience 
as prescribers (Kruskal-Wallis, p<0.05). 
There were no significant differences between medical and non-medical prescribers for 
any of the components (Mann-Whitney U test, p>0.05).  
Content analysis of the responses to the open questions identified that the overwhelming 
perceived benefit was the absence of need for INR monitoring, with the main limitations 
being the lack of a suitable reversal agent and ability to monitor anticoagulation status.
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Discussion 
Statement of key findings 
This survey captured data from mostly experienced medical and non-medical prescribers 
across different settings. PCA of the TDF determinants gave four components of: the role 
of professionals, their knowledge and skills; influences on prescribing; consequences of 
prescribing; and monitoring for safety and effectiveness. While component scores for the 
role of professionals, their knowledge and skills, and influences on prescribing were 
positive, those for the other two components were more neutral. There were low levels 
of agreement for statements relating to more effective, safer and cost-effective 
treatment when prescribing DOACs rather than warfarin. There were similar responses 
around the complexity of bleeding management and detection of over and under-
anticoagulation. The lack of need for INR monitoring was, however, identified as a 
positive aspect of DOAC use.  
 
Strengths and weaknesses 
This study adds to the limited evidence base on prescribers’ perspectives of DOAC use 
for non-valvular AF, as identified in a recently published systematic review [5]. 
Furthermore, this is the first study which based questionnaire items on a theoretical 
framework thus increasing the likely construct and criterion validity. There are, however, 
several limitations to the study hence the findings should be interpreted with caution. 
Although a response rate could not be determined, the number of responses, particularly 
from secondary care, appears low. As a self-reported study it may be subject to biases 
such as social desirability and acquiescence biases. Furthermore, the study was 
conducted in one remote and rural geographical area of Scotland thus the results and 
conclusions may lack external validity. 
 
Interpretation 
This study is both relevant and timely given the increase in DOAC prescribing [24], and 
being the first line recommendation for non-AF management in national and 
international guidelines [1-4]. The consequences of prescribing and monitoring for safety 
and effectiveness had neutral scores. While there was general agreement that 
implementing DOAC guidelines would be good for patients and organisations, there was 
markedly less agreement that patients prescribed DOACs in preference to warfarin would 
be treated more effectively, safely and cost-effectively. At first glance, these findings 
appear contradictory but it may be that prescribers consider guidelines beneficial to 
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patient care but are less aware of the specific evidence from which the guidelines are 
derived. Notably, less experienced prescribers were statistically significantly more 
positive in their responses, which could be as a result of more recent university and 
practice based education and training on DOACs or having less real world experience to 
question the results of even large randomised controlled trials. The majority of 
respondents in a survey of German physicians considered DOACs equally effective as 
warfarin and almost half equally safe [9].  
In terms of monitoring for safety and effectiveness, few respondents disagreed that 
DOAC related bleeding would be more challenging to manage than warfarin. These 
concerns were also identified in previous surveys of European research network centres 
and German physicians [8,9]. Given that idarucizumab is now licensed for use and is 
indicated to reverse dabigatran in patients with life threatening haemorrhage or need for 
urgent surgery [25], and that reversal agents for other DOACs are being developed [26], 
it is likely that these concerns will be abated. Many respondents believed that DOAC 
related over and under-anticoagulation could not easily be detected. Again, less 
experienced prescribers were statistically significantly more positive in their responses. 
Analysis of the open comments also identified this as a potential issue in relation to non-
adherence. The specific site of action of DOACs on the coagulation cascade, together 
with the predictable pharmacokinetic and pharmacodynamic properties and fixed drug 
dosages (other than renal impairment) eliminate the need and usefulness of INR 
monitoring [27].  
The scores for the role of professionals, their knowledge and skills, and influences on 
prescribing were much more positive. Responses indicated self-reported knowledge of 
aspects of DOAC guidelines, evidence base and clinical pharmacology. They were aware 
of how to initiate and monitor DOACs, responding that this was part of their role, and 
that they were generally competent and confident. While there were mixed responses on 
deciding between DOACs and warfarin, local and national guidelines have since been 
updated with DOACs as first line.  
For influences on prescribing, the most negative responses were in relation to cost and 
scrutiny by the health board. Systematic reviews of the cost-effectiveness of DOACs 
compared to warfarin have recommended that, while further real world data are 
required, DOACs are more cost-effective than warfarin despite the higher acquisition 
costs [28,29].   
The specific findings of the more neutral components and statements with negative 
responses should be considered to optimise DOAC prescribing for non-valvular AF. In 
2017, Healthcare Improvement Scotland updated their guidance on the use of DOACs in 
non-valvular AF with the publication of a rapid review of clinical effectiveness [30]. The 
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lack of direct comparisons between DOACs was noted hence the recommendations were 
based entirely on indirect evidence from published network meta-analyses. Edoxaban is 
now recommended as first line treatment for non-valvular AF with the other three DOACs 
being second line. The local guidelines in NHS Highland, along with other healthboards in 
Scotland, have been adapted accordingly. As well as raising awareness of the updated 
guidance, attention should be paid to specific aspects including the evidence base of 
effectiveness, safety and cost effectiveness, management of bleeding, issues of over and 
under-anticoagulation.    
 
Further research 
Qualitative research focusing on the implementation and consequences of the updated 
guidance to prescribe edoxaban is warranted. The consolidated framework for 
implementation research (CFIR) is an appropriate theoretical framework on which to 
base data generation and analysis [31]. 
 
Conclusion 
This study has demonstrated that prescriber respondents in NHS Highland perceive 
themselves to be knowledgeable, confident and competent in the use of DOACs for non-
valvular AF. There was, however, markedly less awareness of the evidence base of the 
effectiveness, safety and cost-effectiveness of DOACs. There were issues around the 
management of DOAC related bleeding and the identification of over and under-
anticoagulation. Further emphasis of these aspects is required during continuing 
professional development, and implementation and evaluation of guidelines.  
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Table 1. Respondent personal and practice demographics (N=154) 
 
Characteristic % (n) 
Profession 
Doctor 
















































































Responses in relation to changing professional practice 
- I resist new ways of working (laggard) 
- I am cautious in relation to new ways of working; I tend to change once most 
of my peers have done so (late majority) 
- I think for some time before adopting new ways of working (early majority) 
- I serve as a role model for others in relation to new ways of working (early 
adopter) 
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Table 2. Approximate frequency of DOAC prescribing behaviours (N=154) 














39.0 (60) 29.2 (45) 26.6 (41) 1.3 (2) 
Switch individual patients from 




18.2 (28) 40.9 (63) 38.3 (59) 1.9 (3) 
Switch individual patients from 
DOACs to warfarin 
 
0 5.2 (8) 
 
31.2 (48) 63.6 (98) 0 
Continue DOACs if initiated by 
others 
 
32.5 (50) 40.3 (62) 
 
10.4 (16) 16.9 (26) 0 
Discontinue DOACs 
 
1.3 (2) 22.7 (35) 
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I have sufficient knowledge of the NHS Highland guideline to allow me 
to prescribe DOACs appropriately 
 
8.0 (11) 62.3 (86) 10.9 (15) 10.1 (14) 4.3 (6) 4.3 (6) 
I have sufficient knowledge of the clinical pharmacology of DOACs to 
allow me to prescribe these safely and effectively 
 
8.0 (11) 58.7 (81) 15.2 (21) 11.6 (16) 2.2 (3) 4.3 (6) 
I have sufficient knowledge of the evidence base of DOACs to allow 
me to prescribe these safely and effectively 
 
8.0 (11) 58.0 (80) 13.0 (18) 13.8 (19) 2.9 (4) 4.3 (6) 
I have sufficient knowledge of how to initiate the prescribing of DOACs 10.1 (14) 65.9 (91) 6.5 (9) 10.9 (15) 1.4 (2) 5.1 (7) 
 
I have sufficient knowledge of how to monitor the effectiveness and 
toxicity of DOACs 
 
6.5 (9) 48.6 (67) 23.9 (33) 14.5 (20) 2.2 (3) 4.3 (6) 
I have sufficient knowledge of how to manage adverse reactions of 
DOACs 
 
5.8 (8) 40.6 (56) 26.1 (36) 20.3 (28) 2.9 (4) 4.3 (6) 
It is part of my role to initiate the prescribing of DOACs 
 
17.4 (24) 52.2 (72) 5.1 (7) 14.5 (20) 5.1 (7) 5.8 (8) 
*I should only prescribe DOACs when they have been initiated by 
others 
 
0.7 (1) 13.0 (18) 5.1 (7) 49.3 (68) 28.3 (39) 3.6 (5) 
*Only specialists should initiate the prescribing of DOACs 
 
0.7 (1) 8.7 (12) 10.1 (14) 54.3 (75) 25.4 (35) 0.7 (1) 
I am confident in my ability to initiate the prescribing of DOACs 
 
13.0 (18) 48.6 (67) 13.0 (18) 15.9 (22) 5.8 (8) 3.6 (5) 
I am competent in initiating the prescribing of DOACs 
 
16.7 (23) 50.0 (69) 14.5 (20) 9.4 (13) 3.6 (5) 5.8 (8) 
I find the guidelines on DOACs easy to interpret 
 
5.1 (7) 37.0 (51) 34.8 (48) 15.2 (21) 1.4 (2) 6.5 (9) 
*I find it difficult to decide whether to prescribe DOACs or warfarin 
 
1.4 (2) 24.6 (34) 9.4 (13) 49.3 (68) 6.5 (9) 8.7 (12) 
*Others have to remind me to prescribe DOACs according to the 
guidelines 
 
0.7 (1) 6.5 (9) 5.1 (7) 62.3 (86) 12.3 (17) 13 (18) 
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I have sufficient support from specialists to enable me to prescribe 
DOACs safely and effectively 
8.7 (12) 60.1 (83) 11.6 (16) 7.2 (10) 0 12.3 (17) 
*I feel anxious when initiating the prescribing of DOACs 
 
0.7 (1) 16.7 (23) 5.1 (7) 50.7 (70) 11.6 (16) 15.3 (21) 
*reverse scored 
Component statistics, sum of allocating 1 (strongly disagree) to 5 (strongly agree)  
Cronbach’s alpha 0.904 
































*Cost is a deterrent to my prescribing of DOACs 
 
3.6 (5) 25.4 (35) 7.2 (10) 47.8 (66) 8.0 (11) 8.0 (11) 
*Potentially increased scrutiny of my prescribing by the health board 
is a deterrent to my prescribing of DOACs 
 




50.7 (70) 13.8 (19) 7.2 (10) 






63.9 (88) 16.7 (23) 7.2 (10) 
*My prescribing of DOAC is discouraged by my organisation 
 
0.7 (1) 9.4 (13) 15.9 (22) 56.5 (78) 10.1 (14) 7.2 (10) 
*My prescribing of DOAC is discouraged by specialists 0.7 (1) 0 
 
12.3 (17) 65.2 (90) 15.2 (21)  6.5 (9) 
* Reverse scored 
Component statistics, sum of allocating 1 (strongly disagree) to 5 (strongly agree)  
Cronbach’s alpha 0.802 





























Implementing the guidelines on prescribing DOACs will be better for 
patients 
 
16.7 (23) 60.1 (83) 18.8 (26) 2.2 (3) 0 2.2 (3) 
Implementing the guidelines on prescribing DOACs will be better for 
my NHS organisation 
 
16.7 (23) 55.8 (77) 
 
23.2 (32)  
 
2.9 (4) 0.7 (1) 0.7 (1) 
If I prescribe DOACs rather than warfarin, I believe that patients will 








32.6 (45) 2.2 (3) 2.2 (3) 
If I prescribe DOACs rather than warfarin, I believe that patients will 
have less adverse effect 
 
5.8 (8) 14.5 (20) 45.7 (63) 29.7 (41) 2.2 (3) 2.2 (3) 
If I prescribe DOACs rather than warfarin, I believe that patients will 
be treated more cost effectively 
 
2.9 (4) 13.8 (19) 47.8 (66) 29.0 (40) 4.3 (6) 2.2 (3) 
Potentially reduced workload in patient monitoring influences my 
prescribing of DOACs rather than warfarin 
 
5.1 (7) 34.8 (48) 7.2 (10) 39.1 (54) 5.8 (8) 8.0 (11) 
Component statistics, sum of allocating 1 (strongly disagree) to 5 (strongly agree)  
Cronbach’s alpha 0.714 
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If I prescribe DOACs rather than warfarin, I believe that my 
management of severe bleeding will be more challenging 
 
10.1 (14) 54.3 (75) 16.7 (23) 15.2 (21) 0.7 (1) 2.9 (4) 
I believe that If I prescribe DOACs rather than warfarin, over-
anticoagulation will not be easily detected 
 




21.7 (30) 0 5.8 (8) 
I believe that If I prescribe DOACs rather than warfarin, under-








21.0 (29) 0.7 (1) 3.6 (5) 
The lack of need for monitoring influences my prescribing of DOACs 
 
10.9 (15) 41.3 (57) 8.7 (12) 24.6 (34) 2.2 (3) 12.3 (17) 
The rurality of my practice influences my prescribing of DOACs 
 
9.4 (13) 29.7 (41) 3.6 (5) 26.1 (36) 2.2 (3) 29 (40) 
Component statistics, sum of allocating 1 (strongly disagree) to 5 (strongly agree)  
Cronbach’s alpha 0.612 
Range possible 5-25, with 25 representing best positive score 
Midpoint 15 
Median 17 
IQR 14-19 
